Related by context. All words. (Click for frequent words.) 71 CIMZIA TM certolizumab pegol 69 sUA 69 hyperphenylalaninemia HPA due 68 HBeAg seroconversion 68 CYT# potent vascular disrupting 68 BENICAR HCT 68 CCyR 68 undetectable HBV DNA 67 Index CDAI 67 CIMZIA ™ 67 serum phosphorous 67 mycophenolate mofetil 67 ACTEMRA TM 67 8mg/kg 67 Solid Tumors criteria 67 MAGE A3 ASCI 67 visilizumab 67 Psoriasis Area 66 complete cytogenetic response 66 cinacalcet 66 achieved ACR# 66 FOLFOX6 66 riociguat 66 dexamethasone Decadron 66 recurrent glioblastoma multiforme 66 corticosteroid dose 66 liver histology 66 MGd 66 tapentadol ER 66 nephrotoxicity 66 serum phosphate 66 CIMZIA TM 66 plus methotrexate 65 mcg BID 65 aspartate aminotransferase AST 65 serum uric acid 65 glycated hemoglobin levels 65 metastatic malignant 65 relapsed MM 65 oral antidiabetic medication 65 alanine aminotransferase ALT 65 adalimumab Humira 65 certolizumab 65 pediatric Crohn disease 65 RECIST Response Evaluation Criteria 65 hA# 65 biochemical relapse 65 TO AVOID PREGNANCY WHILE 65 Crohn Disease Activity 65 VELCADE melphalan 65 ULORIC 65 Cimzia TM 65 MCyR 65 FUSILEV enhances 65 tumor lysis syndrome 65 Scale EDSS 65 elevated ALT 65 colorectal adenoma 65 PEGylated anti 64 COPD exacerbations 64 mCi kg 64 mg BID 64 virologic response 64 PASI scores 64 Traficet EN 64 platelet reactivity 64 teriflunomide 64 clinically meaningful improvement 64 #mg BID [001] 64 fluticasone salmeterol 64 alteplase 64 evaluable subjects 64 Natalizumab 64 vidofludimus 64 DAPT 64 Ocrelizumab 64 corticosteroid therapy 64 hepatic insulin sensitivity 64 evaluating tivozanib 64 pyrazinamide 64 annualized relapse 64 4mg/kg 64 BENICAR 64 CTAP# Capsules 64 APTIVUS r 64 PEGylated Fab fragment 64 infliximab 64 antitumor efficacy 64 pCR 64 salmeterol fluticasone 64 lumbar spine bone 64 HBeAg negative patients 64 ritonavir boosted 64 SGPT 64 calculated creatinine clearance 64 ZOLINZA 64 TNF Tumor Necrosis Factor 64 paricalcitol 64 mg/m2 dose 64 induce remission 64 ara C 64 sustained virological response 64 reduce serum phosphate 64 severe neutropenia 64 mu opioid receptor antagonist 64 psoriatic arthritis PsA 64 β blockers 64 APTIVUS 64 CR nPR 64 autoantibody levels 64 blood Phe levels 64 plasma HCV RNA 64 SCIg 64 Free Survival PFS 64 Pharmacokinetics PK 64 AST ALT 63 adalimumab 63 cis retinoic acid 63 hematological parameters 63 mg QD 63 PSA nadir 63 xanthine oxidase inhibitor 63 blood phenylalanine Phe 63 Adalimumab 63 endoscopic remission 63 glycosylated hemoglobin HbA1c 63 complete remissions 63 partial remissions 63 mg TID 63 MULTAQ 63 imatinib therapy 63 plasma uric acid 63 lumbar spine BMD 63 serum calcium levels 63 relapsing multiple sclerosis 63 ankylosing spondylitis AS 63 severe exacerbations 63 plus prednisone prednisolone 63 refractory chronic lymphocytic 63 PSADT 63 Primary endpoints 63 viral kinetics 63 aminotransferase ALT 63 HBeAg positive patients 63 receiving immunosuppressive therapy 63 cytogenetic response 63 histologically confirmed 63 EXJADE 63 galiximab 63 iPTH 63 serum urate 63 severe renal impairment 63 intestinal mucosal 63 Combination therapy 63 Crohn disease CD 63 ulcerative colitis UC 63 aminotransferases 63 PEGylated interferon beta 1a 63 dasatinib Sprycel 63 systemic corticosteroid 63 5 Fluorouracil 63 steroid dexamethasone 63 K ras mutations 63 macroalbuminuria 63 oral rivaroxaban 63 ribavirin therapy 63 serum clusterin levels 63 trastuzumab Herceptin ® 63 morphometric vertebral fractures 63 steroid refractory ulcerative 63 alanine transaminase ALT 63 sustained virologic response 63 serum HBV DNA 63 oral prodrug 63 abacavir lamivudine 63 moderate renal impairment 63 complete cytogenetic 63 potent CYP#A# inhibitors 63 oxycodone CR 63 virologic suppression 63 SHPT 63 Kinoid 63 GI motility 63 systemic corticosteroids 63 PREZISTA r 63 desvenlafaxine succinate 63 symptomatic VTE 63 sargramostim 63 Oral Fingolimod 63 Pegasys ® 63 PRT# 63 VAPRISOL 63 statin monotherapy 63 HBV DNA levels 63 #.#mg/dL 63 neurologic progression 62 cisplatin gemcitabine 62 C1 INH deficiency 62 vWF 62 radiographic progression 62 candesartan cilexetil 62 myopathy rhabdomyolysis 62 PsA 62 anakinra 62 lenalidomide Revlimid R 62 Etanercept 62 huN# DM1 62 Bezielle 62 posttreatment 62 thrombocytopenic 62 intravascular hemolysis 62 rosuvastatin #mg 62 stage IIIb IV 62 FOLPI 62 primary hypercholesterolemia 62 rFVIIa 62 catheter occlusion 62 octreotide LAR 62 CDAI 62 dapagliflozin plus 62 Nebulized 62 hepatic fibrosis 62 posaconazole 62 tolvaptan 62 serum urate levels 62 Golimumab 62 intravitreal injection 62 standard chemotherapy regimen 62 keloid scarring 62 PSMA ADC 62 response CCyR 62 glycosylated hemoglobin levels 62 phase IIb study 62 decitabine 62 infliximab monotherapy 62 novel VDA molecule 62 hypomagnesemia 62 hepatic metastases 62 Forodesine HCl 62 HSCT 62 pentoxifylline 62 GOUT 62 NATRECOR R 62 leukemia AML 62 HbA1c levels 62 Ranolazine 62 #.#/#.# mmHg [001] 62 ALND 62 ursodeoxycholic acid 62 erythropoietic 62 endometrial hyperplasia 62 virological suppression 62 baseline HbA1c 62 sunitinib Sutent ® 62 STRIDE PD 62 mg BID dose 62 forodesine 62 ACR# [002] 62 selective modulator 62 AGILECT R 62 serum ALT 62 inotropic 62 seropositive patients 62 estramustine 62 somatostatin analog 62 immunosuppressive regimen 62 dose titration 62 lactate dehydrogenase 62 opioid analgesia 62 tipranavir r 62 chemoradiation therapy 62 nab paclitaxel 62 weekly subcutaneous injections 62 ACR# response 62 PROMACTA 62 TREDAPTIVE 62 FOLFOX4 62 mitoxantrone plus 62 airflow obstruction 62 dosage regimens 62 alefacept 62 Severity Index PASI 62 demonstrated clinically meaningful 62 ® lenalidomide 62 elevated serum creatinine 62 serum phosphate levels 62 GAMMAGARD 62 retinal thickness 62 transaminases 62 certolizumab pegol 62 low dose ritonavir 62 octreotide 62 serum phosphorus 62 HbA 1c levels 62 CK # plasma concentrations 62 HBeAg 62 ibandronate 62 Ishak fibrosis score 62 LHRH antagonists 62 B7 H3 62 irbesartan 62 serum aminotransferase levels 62 mg kg dose 62 nadolol 62 myelodysplastic myeloproliferative diseases 62 daunorubicin 62 mucociliary clearance 62 pharmacodynamic PD 62 tiotropium 62 receiving golimumab 62 beta 1a 62 plasma renin activity 62 levodopa therapy 62 CIMZIA R 62 colorectal carcinoma 61 ARIXTRA 61 ADAS Cog 61 recurrent genital herpes 61 baminercept 61 #mg dose [002] 61 chronic eosinophilic leukemia 61 dasatinib Sprycel ® 61 amprenavir 61 dose melphalan 61 IFN α 61 prostate cancer CaP 61 myeloperoxidase 61 mitomycin C 61 TORISEL 61 Androxal TM 61 serum prostate 61 virological response 61 ATACAND 61 haematologic 61 zonisamide SR 61 serum PTH 61 postoperative chemotherapy 61 aldosterone antagonists 61 previously untreated follicular 61 NPH insulin 61 pain palliation 61 Response Evaluation Criteria 61 fosamprenavir 61 oral FTY# 61 airway hydration 61 nicardipine 61 chemosensitivity 61 XIENCE V PROMUS Stent 61 colorectal liver metastases 61 genotypic resistance 61 umol L 61 Pemetrexed 61 sitaxsentan 61 Secondary endpoints 61 Acute Ischemic Stroke 61 Montgomery Asberg Depression 61 R0 resection 61 Non inferiority 61 elevated intraocular pressure 61 sulfasalazine 61 CIPN 61 osteoporotic vertebral compression fractures 61 neurocognitive function 61 PEG IFN 61 HIV HCV coinfected 61 Hepatotoxicity 61 bleeding pallor 61 unresectable tumors 61 Telintra 61 APTIVUS ritonavir 61 primidone 61 DFMO 61 Vidofludimus 61 gout flares 61 Elitek 61 hypophosphatemia 61 pulmonary exacerbations 61 acute GvHD 61 Castration Resistant Prostate Cancer 61 CRp 61 mineral density BMD 61 oral methylnaltrexone 61 oral ridaforolimus 61 lipid parameters 61 #mg/day [002] 61 tocilizumab 61 glomerular filtration 61 detemir 61 Doxil ® 61 inflammatory lesions 61 intravenous bolus 61 interferon ribavirin 61 Meets Primary Endpoint 61 quetiapine XR 61 severe hypersensitivity reactions 61 bFGF 61 prednisone prednisolone plus 61 underlying vasculopathy 61 pT3 61 HuMax EGFr 61 levodopa carbidopa 61 ribavirin RBV 61 QT QTc 61 REVIVE Diabetes 61 hyperalgesia 61 Lp PLA 2 61 glatiramer acetate 61 mesalamine granules 61 IIIa inhibitor 61 biologic therapy 61 Virulizin ® 61 RoACTEMRA 61 nonalcoholic steatohepatitis 61 pegylated liposomal doxorubicin 61 DAS# remission 61 dosing frequency 61 serum testosterone 61 Cimzia R 61 CrCl 61 dose cohort 61 pharmacokinetic PK profile 61 Phase 1a clinical 61 SNT MC# 61 dose escalation phase 61 ACR# responses 61 binary restenosis 61 DAS# CRP 61 sunitinib Sutent 61 busulfan 61 cirrhotic patients 61 Cardiotoxicity 61 oral anticoagulation 61 docetaxel Taxotere ® 61 spontaneous bowel movements 61 biliary tract cancer 61 PROCHYMAL 61 glucose homeostasis 61 antibody MAb 61 aspartate aminotransferase 61 acromegalic patients 61 colectomy 61 Severe Asthma 61 PROCTOCORT ® Suppository Hydrocortisone 61 protease inhibitor PI 61 Flu Cy 61 mL/min/#.# m 2 61 antiarrhythmic drug 61 Secondary endpoints included 61 GnRH agonist 61 ALA PDT 61 elotuzumab 61 inhaled budesonide 61 dose dependently 61 hepatic encephalopathy 61 NAbs 61 azacytidine 61 Alzheimer Disease Assessment 61 ancrod 61 alfa 2a 61 Pegasys plus Copegus 61 VEGF induced 61 hemoglobin A1c HbA1c 61 renal dysfunction 61 prednisone prednisolone 61 antidepressant efficacy 61 mcg QD 61 AVONEX ® 61 doripenem 61 gastrointestinal stromal tumors GIST 61 coadministration 61 CD# upregulation 61 octreotide implant 61 prospectively stratified 61 QTcF 61 mRCC 61 Primary Hypercholesterolemia 61 Hb A1C 61 FASLODEX 61 mycophenolate mofetil MMF 61 icatibant 61 β blocker 61 subependymal giant cell 61 chronic idiopathic thrombocytopenic purpura 61 pamidronate 61 Decitabine 61 Lubiprostone 61 pelvic lymphadenectomy 61 TMC# r 61 salmeterol inhalation powder 61 periprocedural 61 ADCS CGIC 61 steatosis 61 Proteinuria 61 hour bronchodilation 61 Tipranavir 61 Relapsing Remitting Multiple Sclerosis 61 epoetin alpha 61 alicaforsen enema 61 severe renal insufficiency 61 doxorubicin docetaxel 61 mesalazine 61 dose cytarabine 61 Pegylated Liposomal Doxorubicin 61 TNF alpha antagonist 61 bortezomib refractory 61 Critical Limb Ischemia CLI 61 thalidomide Thalomid 61 SGOT 61 refractory NSCLC 61 PRADAXA 61 clodronate 60 deep venous thromboses 60 left ventricular diastolic 60 Acetate Rectal Suppositories 60 cilengitide 60 INCB# [003] 60 lopinavir r arm 60 dual endothelin receptor antagonist 60 systemic hypotension 60 TYGACIL 60 IFN beta 60 hypereosinophilic syndrome 60 salivary flow 60 antitumor effect 60 T2DM 60 Cimzia ® certolizumab pegol 60 dalteparin 60 flutamide 60 posttransplant 60 Ophena TM 60 TRAIL R1 60 SPRYCEL ® 60 mild renal insufficiency 60 Hormone Refractory Prostate Cancer 60 lanthanum carbonate 60 bronchial hyperresponsiveness 60 erlotinib Tarceva ® 60 Thal Dex 60 hemoglobin A1c levels 60 colesevelam HCl 60 lactate dehydrogenase LDH 60 sipuleucel T 60 tipranavir 60 receiving INTRON 60 eculizumab therapy 60 neoadjuvant chemotherapy 60 achieved CCyR 60 Bosentan 60 metabolic alkalosis 60 aPTT 60 EDARBI 60 biologic DMARD 60 tissue oxygenation 60 canakinumab 60 transdermal estradiol 60 lenalidomide dexamethasone 60 Interferon beta 1a 60 opioid induced bowel dysfunction 60 paclitaxel cisplatin 60 elevated transaminases 60 serum lipid levels 60 BYSTOLIC 60 blood Phe 60 oxaliplatin Eloxatin 60 CINQUIL 60 elevated IOP 60 Monotherapy 60 interferon beta therapy 60 Oral corticosteroids 60 atorvastatin #mg 60 BCG refractory 60 serum cortisol 60 metastatic CRC 60 grade cervical intraepithelial 60 prostate cancer CRPC 60 visceral metastases 60 carotid IMT 60 Xanafide 60 RAPTIVA 60 undetectable HCV RNA 60 OAB symptoms 60 liposomal formulation 60 assessing T DM1 60 pertuzumab 60 exhaled nitric oxide 60 imetelstat 60 heavily pretreated patients 60 parathyroid hormone PTH 60 sorafenib tablets 60 GnRH agonists 60 R#/MEM 60 VIIBRYD 60 VA# [002] 60 HMG CoA reductase inhibitors 60 Non Alcoholic Fatty 60 neutropenic patients 60 alagebrium 60 Inhalation Solution 60 dosing cohort 60 #.#g/day 60 timepoints 60 ALT normalization 60 CsA 60 calcineurin inhibitor 60 NLX P# 60 neutropenia dehydration dyspnea 60 LYSTEDA 60 Bortezomib 60 IFN alfa 60 HER2 overexpression 60 plus dexamethasone 60 aplastic anemia AA 60 MoxDuo TM IR 60 interferon gamma 1b 60 rHuPH# 60 nonvertebral fractures 60 receptor blocker 60 bowel resection 60 analgesic efficacy 60 pegylated interferon alfa 60 Neoadjuvant 60 Chemophase 60 anti leukemic 60 azilsartan medoxomil 60 MS relapses 60 budesonide formoterol 60 COPAXONE R 60 virologic failure 60 oral prednisolone 60 hyperphosphatemia 60 gemcitabine Gemzar ® 60 IOP lowering 60 chronic thromboembolic pulmonary 60 VP# [004] 60 serum concentrations 60 budesonide pMDI 60 ADHF 60 Microalbuminuria 60 hypercholesterolemic patients 60 pimozide 60 Degarelix 60 achieved statistical significance 60 Scale EDSS score 60 CDAI score 60 urinary N telopeptide 60 concomitant medications 60 tolterodine ER 60 advanced adenomas 60 unstable angina UA 60 Teriflunomide 60 thromboembolic events 60 lumbar disk herniation 60 NATRECOR ® 60 nonalcoholic steatohepatitis NASH 60 systolic hypertension 60 HIV RNA 60 chemoradiotherapy 60 IV bolus 60 rt PA 60 dose colchicine 60 pyridostigmine 60 INC# 60 metformin sulfonylurea 60 smoldering multiple myeloma 60 Solid Tumors 60 serum potassium 60 IMiDs ® compound 60 vincristine doxorubicin 60 intracranial hemorrhage ICH 60 abatacept 60 Thrombocytopenia 60 metastatic castration resistant 60 creatinine clearance 60 BRAF mutation 60 advanced adenoma 60 MEND CABG 60 intracoronary 60 Thrombotic thromboembolic complications 60 esophageal candidiasis 60 infarct size 60 postoperative AF 60 clinically meaningful improvements 60 HIF PH inhibitors 60 methotrexate therapy 60 Subgroup analysis 60 adjuvant radiation 60 randomized multicenter trial 60 HES CEL 60 eosinophilic asthma 60 p# activation 60 superficial bladder cancer 60 hematologic toxicity 60 fosbretabulin 60 Myelodysplastic Syndrome MDS 60 carcinoembryonic antigen 60 Dasatinib 60 atazanavir ritonavir 60 decompensated liver disease 60 palifermin 60 headache nasopharyngitis 60 REMICADE ® 60 weekly intravenous infusions 60 Interferon alpha 60 probiotic supplementation 60 fondaparinux 60 primary generalized tonic 60 salmeterol HFA MDI 60 NIHSS 60 adenotonsillectomy 60 Mg Uk 60 antidiabetic drug 60 remission CR 60 mTOR mammalian target 60 RSD# oral 60 dopaminergic therapy 60 pT2 60 pharmacodynamic profiles 60 divalproex sodium 60 Vidaza azacitidine 60 clinically meaningful 60 placebo controlled clinical 60 highly emetogenic 60 azathioprine 60 alanine aminotransferase 60 gemcitabine cisplatin 60 brivaracetam 60 hepatic enzymes 60 alkaline phosphatase ALP 60 custirsen 60 microbiological eradication 60 liver metastasis 60 bevacizumab Avastin ® 60 hormone receptor negative 60 Eltrombopag 60 neoadjuvant 60 KRAS mutant tumors 60 phase IIb trial 60 aplindore 60 pomalidomide 60 alkylating agent 60 doxorubicin cyclophosphamide 60 HbA1C 60 hsCRP levels 60 INCB# [001] 60 plasma pharmacokinetics 60 Durezol 60 antiandrogens 60 bronchodilation 60 aminotransferase elevations greater 60 variceal hemorrhage 60 stage IIIB 60 Aptivus ® 60 detectable HCV RNA 60 schizophrenia CIAS 60 vapreotide acetate 60 protein tyrosine phosphatase 1B 60 intravitreal injections 60 briakinumab 60 urate lowering therapy 60 Relapsed Refractory 60 INSPIRE Trial Phase III 60 DOXIL 60 EDSS scores 60 lumiliximab 60 ACR# ACR# 60 troponin T 60 androgen deprivation 60 mm Stent 60 ertapenem 60 rFSH 60 INVEGA ® 60 heavily pretreated 60 serum uric acid sUA 60 A1c levels 60 QD dosing 60 q#h 60 hepatocellular 59 splenectomized patients 59 lanreotide 59 lamivudine refractory patients 59 cell lymphoma CTCL 59 prostanoid 59 mg RDEA# 59 aminotransferase levels 59 COPD exacerbation 59 growth hormone secretion 59 homozygous familial hypercholesterolemia 59 systemic anaplastic large 59 CCX# B 59 carboplatin paclitaxel 59 CorVue ™ 59 hypercalcemia 59 receiving prophylactic anticoagulation 59 solifenacin 59 mL/min/#.# m2 59 favorable tolerability 59 CDK inhibitor 59 PREZISTA r arm 59 GnRH antagonist 59 antitumor activity 59 FluCAM 59 mGluR5 negative 59 ABVD 59 resected pancreatic cancer 59 squamous histology 59 #mg/m# [001] 59 apolipoprotein B 59 sUA levels 59 ARIKACE 59 debulking surgery 59 viral suppression 59 hypogonadal men 59 clopidogrel Plavix 59 Benign Prostatic Hyperplasia BPH 59 progression TTP 59 dose proportionality 59 Naive Patients 59 neutrophil count 59 confirmed CCyR 59 receiving VELCADE 59 Tolvaptan 59 clomipramine 59 maximal tolerated 59 activated partial thromboplastin 59 nephrotoxic drugs 59 curative resection 59 idarubicin 59 graft occlusion 59 mg/m2 cohort 59 neutrophil counts 59 prostate carcinoma 59 CR CRu 59 metastatic GIST 59 DLTs 59 parathyroidectomy 59 minimally symptomatic 59 HER2 expression 59 blood glucose concentrations 59 radiochemotherapy 59 trans retinoic acid 59 specific antigen PSA 59 Hb levels 59 CYPHER Stent 59 timepoint 59 triglyceride concentrations 59 node metastases 59 titrated glipizide 59 RBC transfusions 59 recurrent VTE 59 RECIST criteria 59 leukemia ALL 59 non splenectomized 59 Tumor Response 59 LEXIVA r 59 insulin detemir 59 patients evaluable 59 TNF antagonist 59 T1DM 59 urothelial carcinoma 59 cytoreductive surgery 59 DAVANAT 59 paraprotein 59 left ventricular systolic 59 bosentan 59 KAPIDEX 59 OSAHS 59 5-FU/LV 59 FOLPI regimen 59 immunomodulatory therapy 59 basiliximab 59 Vaprisol 59 idraparinux 59 Aflibercept 59 pegfilgrastim 59 triiodothyronine 59 cytogenetic responses 59 anagrelide 59 heparin induced thrombocytopenia 59 proliferative diabetic retinopathy 59 baseline LDH 59 fasting glucose levels 59 locoregional recurrence 59 mixed hyperlipidemia 59 Pioglitazone 59 mg/# hr 59 epoetin beta 59 Adjuvant chemotherapy 59 odanacatib 59 natriuresis 59 adenoma recurrence 59 thyrotropin levels 59 serum PSA 59 intradermal injections 59 FOSRENOL ® 59 hemodialysis patients 59 cardiac toxicity 59 #mg doses [002] 59 Secondary endpoints include 59 Trastuzumab 59 antioxidant supplementation 59 systolic dysfunction 59 hemorrhagic complications 59 liver transaminases 59 bendamustine 59 tegaserod 59 intratumoral 59 peritumoral brain edema 59 CYT# QbG# 59 corticosteroid dexamethasone 59 renal toxicity 59 diabetic gastroparesis 59 antihypertensive therapy 59 febuxostat 59 μmol L 59 Capesaris 59 Tarceva TM 59 Neovascular Age Related Macular 59 R# #mg BID 59 HuLuc# 59 pegaptanib 59 Octreolin 59 peripheral sensory neuropathy 59 spontaneous bacterial peritonitis 59 recovery CRp 59 basal cell nevus syndrome 59 Study GL# 59 macrovascular 59 secretory phospholipase A2 sPLA2 59 adrenal function 59 mepolizumab 59 peg interferon 59 moderate ulcerative colitis 59 Rating Scale MADRS 59 placebo dexamethasone 59 FIRMAGON 59 severe oral mucositis 59 Phe restricted diet 59 evaluating Actimmune 59 proctitis 59 AVODART 59 Enzastaurin 59 LEXIVA 59 FDG PET imaging 59 APRISO 59 Folfox 59 variceal bleeding 59 nondiabetic patients 59 pruritus itching 59 secondary efficacy endpoint 59 #beta HSD1 59 Complicated Skin 59 Glypromate 59 leucopenia 59 dose Iluvien 59 weekly CSBMs 59 fluvastatin 59 mg kg REMICADE 59 HBeAg negative 59 TMS Therapy 59 Parathyroid hormone 59 μg kg 59 sub maximal 59 avosentan 59 receptor tyrosine kinase inhibitor 59 prolactin elevation 59 recurrent NSCLC 59 Noxafil 59 Thiazolidinediones 59 platelet inhibitor 59 antiangiogenic 59 mg qd 59 fasting plasma glucose 59 plus MTX 59 cTnI 59 CoFactor 59 zoledronate 59 hypokalemia 59 F FDG PET 59 tirofiban 59 MDS MPD 59 Infusion Reactions Severe 59 systemic immunosuppressive 59 nucleotide analog 59 intravenous iv 59 ropivacaine 59 postoperative inflammation 59 secondary hyperparathyroidism 59 methotrexate monotherapy 59 conventional DMARDs 59 fluorouracil 59 inhibit platelet function 59 recurrent GBM 59 mcg kg REBETOL 59 Heterozygous Familial Hypercholesterolemia 59 Vimpat R 59 Cyclosporine 59 progressive dyspnea 59 achieve sustained virologic 59 #ß